On November 20, EVEREST MED fell 4.01% in Regular Trading, trading at HK$22.04, with turnover of HK$19.715 million.
The latest disclosed development was the first patient dosed in the Phase 2b ASCEND trial of VIS-101 for wet age-related macular degeneration, but the update reflects an early-stage clinical milestone with no immediate earnings contribution, limiting near-term support for the shares.
Company disclosures indicate the China study plans to enroll about 244 patients and compares 6 mg and 9 mg VIS-101 against 2 mg aflibercept given every eight weeks, with results intended to support dose selection for global Phase 3 trials. The stock had also recently reacted to medical insurance inclusion news for two products and the renewal of another, making the latest R&D progress less effective as a fresh trading driver.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments